Recce Pharmaceuticals Ltd
ASX:RCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its Industry Average (18.8), the stock would be worth AU$-0.27 (157% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -33.2 | AU$0.48 |
0%
|
| Industry Average | 18.8 | AU$-0.27 |
-157%
|
| Country Average | 1.7 | AU$-0.02 |
-105%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
138.8m AUD | -33.2 | -4.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 9.5 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 3.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 2.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 1.1 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.7 |
| 70th Percentile | 3.5 |
| Max | 3 073.7 |
Other Multiples
Recce Pharmaceuticals Ltd
Glance View
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.
